6th Nov 2024 16:52
(Alliance News) - EDX Medical Group PLC on Wednesday said that it has signed an exclusive distribution agreement with mirdetect GmbH to distribute its M371 testicular cancer diagnostic test.
EDX Medical is a Cambridge, England-based company that develops digital diagnostic products and services to treat cancer, heart disease, and infectious diseases.
The M371 test is a blood test that enables detection of critical biomarkers of testicular cancer in its early stages, the most common form of cancer among young men. According to the deal, mirdetect will distribute the test to the UK, Sweden, Finland, Norway and Denmark.
"We are very pleased to be appointed as the exclusive distributor of the M371-Test in several countries, which is an excellent fit with our range of diagnostics which enable healthcare professionals to personalise and optimise treatment decisions for all patients. EDX Medical expects to continue to work with mirdetect in future to further refine and develop the test and associated services," said Chief Executive Officer Mike Hudson.
Shares in EDX Medical Group last traded at 9.50 pence each on Aquis on Wednesday afternoon.
By Holly Beveridge, Alliance News senior reporter
Comments and questions to [email protected]
Copyright 2024 Alliance News Ltd. All Rights Reserved.